- Home
- NATH vs CLLS Comparison
NATH vs CLLS Comparison
Compare NATH & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NATH | CLLS |
|---|---|---|
| Founded | 1916 | 1999 |
| Country | United States | France |
| Employees | 131 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 384.3M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NATH | CLLS |
|---|---|---|
| Price | $100.65 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 21.0K | ★ 48.3K |
| Earning Date | 02-05-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 22.29 | N/A |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $104,201,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $88.00 | $1.10 |
| 52 Week High | $118.32 | $5.48 |
Technical Indicators
Market Signals| Indicator | NATH | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 42.08 |
| Support Level | $100.25 | $3.32 |
| Resistance Level | $101.86 | $3.83 |
| Average True Range (ATR) | 0.45 | 0.21 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 60.00 | 22.37 |
Price Performance
Historical ComparisonAbout NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.